Merck KGaA (FRA:MRKC) Total Equity: €29,819 Mil (As of Mar. 2026)


FRA:MRKC Merck KGaA FRA:MRKC
82 GF Score
Price €29.20
GF Value €28.20
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Total Equity?

Merck KGaA FRA:MRKC +2.10% 82 Total Equity is €29,819 Mil as of Mar. 2026. GuruFocus rates FRA:MRKC with a GF Score™ of 82/100 and a GF Value™ of €28.20 (Fairly Valued). The stock has 9 warning signs investors should review.

Merck KGaA's total equity for the quarter that ended in Mar. 2026 was €29,819 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Merck KGaA Total Equity Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Total Equity Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21,416.00 26,005.00 26,755.00 29,989.00 28,660.00

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29,898.00 28,328.00 29,000.00 28,660.00 29,819.00
FRA:MRKC
82GF Score
Merck KGaA FRA:MRKC
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Merck KGaA's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=51527-22867
=28,660

Merck KGaA's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=53070-23251
=29,819

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €29,819 Mil mean?
Merck KGaA (FRA:MRKC) has a Total Equity of €29,819 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Merck KGaA and its competitors.
Is Merck KGaA's Total Equity too high?
Merck KGaA's current Total Equity is €29,819 Mil. Overall, Merck KGaA has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Total Equity compare to ZTS and UTHR?
Merck KGaA's Total Equity of €29,819 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Merck KGaA and its competitors. Merck KGaA's current Total Equity is €29,819 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (FRA:MRKC) is currently considered Fairly Valued. The stock's GF Value™ is €28.20, compared to a current price of €29.20 — trading 3.5% above its estimated fair value. The current Total Equity is €29,819 Mil. Merck KGaA's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Merck KGaA (FRA:MRKC), the current Total Equity is €29,819 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (FRA:MRKC) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of €29.20 is trading 3.5% above its estimated GF Value™ of €28.20. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for FRA:MRKC:

  • Total Equity: €29,819 Mil
  • GF Value™: €28.20 vs. price of €29.20 (3.5% above fair value)
  • GF Score™: 82/100 with 9 warning signs

No single metric tells the full story. See the FRA:MRKC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
82GF Score

Get the complete analysis for FRA:MRKC

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.20
Price
€28.20
GF Value